Development of a novel ectonucleotidase assay suitable for high-throughput screening.
about
High-throughput screening identifies idarubicin as a preferential inhibitor of smooth muscle versus endothelial cell proliferationCombining phenotypic and proteomic approaches to identify membrane targets in a 'triple negative' breast cancer cell typeDevelopment, validation and quantitative assessment of an enzymatic assay suitable for small molecule screening and profiling: A case-studyTargeting CD73 in the tumor microenvironment with MEDI9447.Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action.Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
P2860
Development of a novel ectonucleotidase assay suitable for high-throughput screening.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Development of a novel ectonucleotidase assay suitable for high-throughput screening.
@en
Development of a novel ectonucleotidase assay suitable for high-throughput screening.
@nl
type
label
Development of a novel ectonucleotidase assay suitable for high-throughput screening.
@en
Development of a novel ectonucleotidase assay suitable for high-throughput screening.
@nl
prefLabel
Development of a novel ectonucleotidase assay suitable for high-throughput screening.
@en
Development of a novel ectonucleotidase assay suitable for high-throughput screening.
@nl
P2093
P2860
P356
P1476
Development of a novel ectonucleotidase assay suitable for high-throughput screening.
@en
P2093
Erin Brand
Kim Rosenthal
Kris F Sachsenmeier
Lori Clarke
Ralph Minter
Robert Hollingsworth
Sandrine Guillard
Steven Rust
P2860
P304
P356
10.1177/1087057112443987
P577
2012-04-20T00:00:00Z